Insulin and type 1 diabetes: immune connections

被引:29
|
作者
Culina, Sloboda [1 ,2 ]
Brezar, Vedran [1 ,2 ]
Mallone, Roberto [1 ,2 ,3 ]
机构
[1] Hop St Vincent de Paul, INSERM, U986, DeAR Lab Avenir, F-75674 Paris 14, France
[2] Paris Descartes Univ, Fac Med, Paris, France
[3] Hop Hotel Dieu, AP HP, Serv Diabetol, Paris, France
关键词
BETA-CELL FUNCTION; ANTIBODY STANDARDIZATION PROGRAM; THYMIC EPITHELIAL-CELLS; ALTERED-PEPTIDE LIGAND; AUTOREACTIVE T-CELLS; ORAL INSULIN; NOD MICE; 1ST-DEGREE RELATIVES; GENE-EXPRESSION; DENDRITIC CELLS;
D O I
10.1530/EJE-12-0693
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin is the hormone produced by pancreatic beta-cells, with a central role in carbohydrate and fat metabolism. Together with its precursors preproinsulin and proinsulin, insulin is also a key target antigen (Ag) of the autoimmune islet destruction leading to type 1 diabetes. Being recognized by both autoantibodies (aAbs) and autoreactive T cells, insulin plays a triggering role, at least in rodent models, in diabetes pathogenesis. It is expressed not only by beta-cells but also in the thymus, where it plays a major role in central tolerance mechanisms. We will summarize current knowledge concerning insulin, its role in beta-cell autoimmunity as initial target Ag, its recognition by aAbs and autoreactive T cells, and the detection of these immune responses to provide biomarkers for clinical trials employing insulin as an immune modulatory agent. European Journal of Endocrinology 168 R19-R31
引用
收藏
页码:R19 / R31
页数:13
相关论文
共 50 条
  • [1] Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes
    Lindholm, A
    Jensen, LB
    Home, PD
    Raskin, P
    Boehm, BO
    Råstam, J
    DIABETES CARE, 2002, 25 (05) : 876 - 882
  • [2] IMMUNE MODULATION BY METHIMAZOLE IN TYPE 1 (INSULIN-DEPENDENT) DIABETES
    WALDHAUSL, W
    BRATUSCHMARRAIN, P
    VIERHAPPER, H
    PIRICH, K
    DIABETOLOGIA, 1987, 30 (07) : A595 - A595
  • [3] Immune mechanisms leading to type 1 insulin-dependent diabetes mellitus
    Boitard, C
    Timsit, J
    Larger, E
    Dubois, D
    HORMONE RESEARCH, 1997, 48 : 58 - 63
  • [4] Changes in insulin, glucagon and ER stress precede immune activation in type 1 diabetes
    Crookshank, Jennifer A.
    Serrano, Daniel
    Wang, Gen-Sheng
    Patrick, Christopher
    Morgan, Baylie S.
    Pare, Marie-France
    Scott, Fraser W.
    JOURNAL OF ENDOCRINOLOGY, 2018, 239 (02) : 181 - 195
  • [5] Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes
    Ergun-Longmire, B
    Marker, J
    Zeidler, A
    Rapaport, R
    Raskin, P
    Bode, B
    Schatz, D
    Vargas, A
    Rogers, D
    Schwartz, S
    Malone, J
    Krischer, J
    Maclaren, NK
    ORAL TOLERANCE: NEW INSIGHTS AND PROSPECTS FOR CLINICAL APPLICATION, 2004, 1029 : 260 - 277
  • [6] THE IMMUNE GENOTYPE IN TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS
    MILLWARD, BA
    DEMAINE, A
    HITMAN, GA
    SACHS, J
    CASSEL, PG
    WELSH, K
    LESLIE, RDG
    PYKE, DA
    DIABETOLOGIA, 1986, 29 (08) : A571 - A571
  • [7] TYPE 1 DIABETES: BEYOND INSULIN
    Kazeem, O.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A241 - A241
  • [8] Inhaled insulin in type 1 diabetes
    Cavallo, MG
    Coppolino, G
    Romeo, S
    Pozzilli, P
    LANCET, 2001, 357 (9272): : 1980 - 1980
  • [9] Insulin Therapy in Type 1 Diabetes
    Stephens, Elizabeth
    MEDICAL CLINICS OF NORTH AMERICA, 2015, 99 (01) : 145 - +
  • [10] Insulin therapy in type 1 diabetes
    Renner, R
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S30 - S33